Medicine

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

R. Stupp, M. Hegi, W. Mason, M. J. van den Bent, M. Taphoorn, Robert C. Janzer, S. Ludwin, A. Allgeier, B. Fisher, K. Bélanger, P. Hau, A. Brandes, J. Gijtenbeek, C. Marosi, C. Vecht, K. Mokhtari, P. Wesseling, S. Villà, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J. G. Cairncross, R. Mirimanoff

2009.5.1LANCET ONCOLOGY

DOI: 10.1016/s1470-2045(09)70025-7

tlooto Summary

Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.

Abstract

Abstract is not available.

Citation format

STUPP, R., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. LANCET ONCOLOGY, 2009, 10 5: 459–66.